Adding UDIs To Claims Is Crucial for Device Surveillance, Pew Tells Congress
This article was originally published in The Gray Sheet
Executive Summary
Incorporating unique device identifiers into insurance claims is necessary to leverage FDA’s Sentinel postmarket surveillance initiative to devices, Josh Rising of The Pew Charitable Trusts emphasized to House lawmakers at a recent hearing.
You may also be interested in...
Clinical Registries Need Streamlining To Reap Benefits, Mussallem Tells Congress
Clinical registries can yield useful information on patient outcomes that can support approval, reimbursement and care decisions but the benefits of registries need to be balanced against their costs, Edwards Lifesciences CEO Michael Mussalem told a House Energy and Commerce subcommittee July 22.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.